Unknown

Dataset Information

0

Efficacy of Human Exposures of Gepotidacin (GSK2140944) against Escherichia coli in a Rat Pyelonephritis Model.


ABSTRACT: Gepotidacin is a first-in-class triazaacenaphthylene antibacterial that inhibits bacterial type II topoisomerases and has in vitro activity against a range of bacterial pathogens, including Escherichia coli Urinary tract infections often progress to pyelonephritis and are a worldwide problem due to the prevalence of multidrug-resistant E. coli strains. This study evaluated the in vivo efficacy of gepotidacin against four strains of multidrug-resistant E. coli in a rat pyelonephritis model. Infected rats received controlled intravenous infusions of gepotidacin every 12?h for 4?days that recreated human systemic exposures from oral gepotidacin (800?or 1,500?mg twice daily for 4?days). Liquid chromatography-tandem mass spectrometry analysis of blood samples and kidney homogenates showed that gepotidacin levels were 6- to 7-fold higher in kidneys than in blood. Across experiments with 4-day gepotidacin treatments, bacterial CFU in kidneys were reduced by 2.9 to 4.9 log10 compared to pretreatment levels, and bladder CFU were reduced to the lower limit of detection (1.2 log10). The efficacies of 800- and 1,500-mg gepotidacin exposures were statistically similar. A time-course experiment indicated that a period of more than 24?h of gepotidacin treatment was required for efficacy and that 4?days were needed for maximal response. Overall, these results demonstrate that the recreated human exposures of gepotidacin studied were effective in an animal model of pyelonephritis caused by multidrug-resistant E. coli and that further evaluation for clinical use is warranted.

SUBMITTER: Hoover JL 

PROVIDER: S-EPMC6591613 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy of Human Exposures of Gepotidacin (GSK2140944) against <i>Escherichia coli</i> in a Rat Pyelonephritis Model.

Hoover Jennifer L JL   Singley Christine M CM   Elefante Philippa P   Rittenhouse Stephen S  

Antimicrobial agents and chemotherapy 20190624 7


Gepotidacin is a first-in-class triazaacenaphthylene antibacterial that inhibits bacterial type II topoisomerases and has <i>in vitro</i> activity against a range of bacterial pathogens, including <i>Escherichia coli</i> Urinary tract infections often progress to pyelonephritis and are a worldwide problem due to the prevalence of multidrug-resistant <i>E. coli</i> strains. This study evaluated the <i>in vivo</i> efficacy of gepotidacin against four strains of multidrug-resistant <i>E. coli</i> i  ...[more]

Similar Datasets

| S-EPMC5328517 | biostudies-other
| S-EPMC6927889 | biostudies-literature
| S-EPMC5487655 | biostudies-literature
| S-EPMC7104652 | biostudies-literature
| S-EPMC8218671 | biostudies-literature
| S-EPMC7318048 | biostudies-literature
| S-EPMC3294818 | biostudies-literature
| S-EPMC5444153 | biostudies-literature
2008-06-15 | E-GEOD-7087 | biostudies-arrayexpress
| S-EPMC8923173 | biostudies-literature